The small sample size of our SP-HUS cohort (13 patients) does not allow to achieve statistically significant conclusions when comparing the frequency of the common genetic variants MCPggaac, CFH(H3), CFHR3*B, and CFHR1*B with control individuals, or with the aHUS cohort (Table 2). This evidence concerns the gene CFHR3 and hemolytic-uremic syndrome.